Current perspectives suggest that balancing lipid metabolism in the CNS is a crucial approach to treat AD, and various APOA-I mimetics and activators have been shown to modulate lipid metabolism in glial cells, alleviating AD pathology. The gene discussed is APOA1; the disease is Alzheimer disease.